Steven Narod
Overview
Explore the profile of Steven Narod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
3891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al.
Hered Cancer Clin Pract
. 2024 Sep;
22(1):19.
PMID: 39300540
Objective: To investigate whether Molybdenum blood level is a marker of cancer risk on BRCA1 carriers. Methods: A prospective cohort study was conducted among 989 initially unaffected women with a...
2.
Shah C, Whitworth P, Vicini F, Narod S, Gerber N, Jhawar S, et al.
Ann Surg Oncol
. 2024 Jun;
31(9):5919-5928.
PMID: 38916700
Background: Breast-conserving surgery (BCS) followed by adjuvant radiotherapy (RT) is a standard treatment for ductal carcinoma in situ (DCIS). A low-risk patient subset that does not benefit from RT has...
3.
Zamani N, Szymiczek A, Shakeri R, Poustchi H, Pourshams A, Narod S, et al.
PLoS One
. 2023 Nov;
18(11):e0292611.
PMID: 37943872
Esophageal squamous cell carcinoma (ESCC) has a very high incidence rate in northeastern Iran. Our team previously reported the BReast CAncer gene 2 (BRCA2) p.K3326* mutation as a moderately penetrant...
4.
Cybulski C, Zamani N, Kluzniak W, Milano L, Wokolorczyk D, Stempa K, et al.
Am J Hum Genet
. 2023 Mar;
110(4):648-662.
PMID: 36977412
Several breast cancer susceptibility genes have been discovered, but more are likely to exist. To identify additional breast cancer susceptibility genes, we used the founder population of Poland and performed...
5.
Villarreal-Garza C, Ferrigno A, Aranda-Gutierrez A, Frankel P, Ruel N, Fonseca A, et al.
Cancer Res Commun
. 2022 Jul;
1(3):140-147.
PMID: 35875314
The presence of pathogenic variants (PVs) in triple-negative breast cancer (TNBC) is associated with a distinctive genomic profile that makes the tumor particularly susceptible to DNA-damaging treatments. However, patients with...
6.
Howell D, Metcalfe K, Kong S, Stephen J, Olivotto I, Baxter N, et al.
Breast Cancer Res Treat
. 2022 Apr;
194(1):91-102.
PMID: 35462611
Purpose: Young women with breast cancer (YWBC) are an understudied population and there are limited data on risk factors for psychological morbidity early in diagnosis. We examined psychological morbidity (anxiety,...
7.
Carmona C, Yee S, Seminsky M, Glass K, Foong S, Lipson E, et al.
Ann Surg Oncol
. 2022 Jan;
29(5):3022-3033.
PMID: 35001240
Background: Prompt referral by their surgeon enables fertility preservation (FP) by young women with breast cancer (YWBC) without treatment delay. Following a FP knowledge intervention, we evaluated surgeon and patient...
8.
Marciniak W, Matousek T, Domchek S, Angelo Paradiso , Patruno M, Irmejs A, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34283078
An important group of breast cancers is those associated with inherited susceptibility. In women, several predisposing mutations in genes involved in DNA repair have been discovered. Women with a germline...
9.
Clark R, Kenk M, McAlpine K, Thain E, Farncombe K, Pritchard C, et al.
Can Urol Assoc J
. 2021 Jun;
15(12):E623-E629.
PMID: 34171218
Prostate cancer is a significant cause of cancer mortality. It has been well-established that certain germline pathogenic variants confer both an increased risk of being diagnosed with prostate cancer and...
10.
Pujol P, Barberis M, Beer P, Friedman E, Piulats J, Capoluongo E, et al.
Eur J Cancer
. 2021 Feb;
146:30-47.
PMID: 33578357
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of...